M&A Deal Summary |
|
---|---|
Date | 2021-12-14 |
Target | VCN |
Sector | Life Science |
Buyer(s) | Theriva Biologics |
Sellers(s) | Grifols |
Deal Type | Divestiture |
Deal Value | 75M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Sector | Life Science |
Employees | 22 |
Revenue | 21M USD (2023) |
Theriva Biologics is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. Theriva Biologics is based in Rockville, Maryland.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (Spain) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
Category | Company |
---|---|
Founded | 1909 |
Sector | Healthcare Services |
Employees | 23,000 |
Revenue | 6.6B EUR (2023) |
Grifols is a global healthcare company and biopharmaceutical manufacturer. Grifols was founded in 1909 and is based in Barcelona, Spain.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (Spain) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-09-17 |
Biotest
Dreieich, Germany Biotest specializes in innovative hematology and clinical immunology solutions. The company develops, produces and markets biological medicinal products with applications in hematology, clinical immunology and intensive care. It's current portfolio includes 12 different products with a global commercial footprint in more than 90 countries. Biotest was founded in 1946 and is based in Dreieich, Germany. |
Buy | €1.6B |